Stockholders’ Deficit (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended							9 Months Ended	12 Months Ended
	Feb. 02, 2021	Oct. 31, 2021	Jul. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 29, 2021	Mar. 23, 2021	Feb. 28, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Nov. 10, 2015
Stockholders’ Deficit (Details) [Line Items]
Capital stock, description										(i) 100 million shares of common stock, $0.001 par value, and (ii) 2 million shares of preferred stock, $0.001 par value, designated as Series A convertible preferred stock. In December 2015, we amended our Certificate of Incorporation to change our authorized capital stock to provide for 15 million authorized shares of preferred stock of which 7,515,000 was designated as Series B convertible preferred stock, par value $.001 per share.
Common stock, shares authorized										100,000,000	100,000,000
Common stock, shares issued										12,207,283	5,099,512
Common stock, share outstanding										12,207,283	5,099,512
Aggregate of shares, private placement offering								4,188,854
Net proceeds (in Dollars)					$ 3,523
Aggregate of shares, direct offering					1,975,000
Aggregate of shares, exercise of common stock warrants		922,966	922,966	922,966	922,966
Generating net proceeds (in Dollars)		$ 1,250	$ 1,250	$ 1,250	$ 1,250
Aggregate of shares,, restricted stock units									20,951
Common stock, par value (in Dollars per share)										$ 0.001	$ 0.001
Registered direct offering, description							On March 23, 2021, we consummated a registered direct offering with certain institutional investors and issued an aggregate of 1,975,000 shares of our common stock, par value $0.001 per share at a purchase price of $2.00 per share for gross proceeds to us of approximately $3.95 million, pursuant to a prospectus, dated August 24, 2018, and a prospectus supplement, dated March 22, 2021, in connection with a takedown from our shelf registration statement on Form S-3 (File No. 333-225712).
Aggregate of shares, description										On March 19, 2021, June 22, 2021, July 15, 2021 and October 7, 2021, we issued an aggregate of 700, 680, 499, 5,616 and 16,171 shares of commons stock for the exercise of certain warrants, respectively. The net proceeds to us for these exercises was $1,250.
Placement Agent Warrants [Member]
Stockholders’ Deficit (Details) [Line Items]
Purchase of aggregate shares										148,125
Exercise price per share (in Dollars per share)										$ 2.5
Common Stock [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock, shares authorized												100,000,000
Common stock, shares issued										12,207,283
Common stock, share outstanding										5,099,512
Shares issued										7,107,771
Preferred Stock [Member]
Stockholders’ Deficit (Details) [Line Items]
Preferred stock, shares authorized												10,000,000
Private Placement [Member]
Stockholders’ Deficit (Details) [Line Items]
Net proceeds (in Dollars)								$ 8,898
Aggregate shares	3,968,854
Common stock, par value (in Dollars per share)	$ 0.001
Purchase price per share (in Dollars per share)	$ 2.2785
Aggregate shares of common stock	420,000
Purchase price of pre-funded warrants (in Dollars per share)	$ 2,277.5000
Purchase of aggregate shares	2,194,427
Gross proceeds (in Dollars)	$ 10,000
Pre-funded shares, description						At March 29, 2021, all 420,000 pre-funded shares had been distributed. In connection with the offering, we issued the placement agent warrants to purchase up to 329,164 shares of common stock with an exercise price of $2.8481 per share.